Snowbird Resort Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2005
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Chromatin Modification Pathways (C7)
Organizer(s) Tony Kouzarides and Shelley L. Berger
March 31—April 5, 2005
Snowbird Resort • Snowbird, UT USA
Abstract Deadline: Nov 30, 2004
Late Abstract Deadline:
Scholarship Deadline:
Early Registration Deadline: Jan 31, 2005
Sponsored by Novartis Institutes for BioMedical Research and The Director's Fund
Summary of Meeting:
It has become apparent over the last few years that histone modifications mediate important biological functions. There is a plethora of these modifications and new ones are being discovered on a regular basis. These modifications are most commonly being studied in the context of transcriptional regulation, since classically modifications on histones were correlated with transcriptional state. However, it is now clear that any biological process involving DNA may be affected and regulated by histone modifications. As a result there are now indications that biological processes such as repair, replication and recombination are also under the control of histone modifications. Another recent development has been the mechanistic link between histone modifications and distinct processes involving nucleic acids such as DNA methylation and RNA interference. Each of these processes are under scrutiny in their own right, but the recent data suggests that each of these is intimately linked with histone modifications in the formation of heterochromatin structures which regulate transcription. Finally, data is now amassing that histone-modifying enzymes are linked to cancer. Inhibitors of deacetylases are now in phase I and II clinical trials and modifying enzymes are found over expressed, mutated and rearranged in cancer cells. The potential of these enzymes for radional drug discovery is therefore only now beginning to be realized. The aim of this meeting is to focus on basic research involving the normal biological functions relating to histone modifications and to highlight the pathways and enzymes that are deregulated in cancer cells.
View Scholarships/Awards
It has become apparent over the last few years that histone modifications mediate important biological functions. There is a plethora of these modifications and new ones are being discovered on a regular basis. These modifications are most commonly being studied in the context of transcriptional regulation, since classically modifications on histones were correlated with transcriptional state. However, it is now clear that any biological process involving DNA may be affected and regulated by histone modifications. As a result there are now indications that biological processes such as repair, replication and recombination are also under the control of histone modifications. Another recent development has been the mechanistic link between histone modifications and distinct processes involving nucleic acids such as DNA methylation and RNA interference. Each of these processes are under scrutiny in their own right, but the recent data suggests that each of these is intimately linked with histone modifications in the formation of heterochromatin structures which regulate transcription. Finally, data is now amassing that histone-modifying enzymes are linked to cancer. Inhibitors of deacetylases are now in phase I and II clinical trials and modifying enzymes are found over expressed, mutated and rearranged in cancer cells. The potential of these enzymes for radional drug discovery is therefore only now beginning to be realized. The aim of this meeting is to focus on basic research involving the normal biological functions relating to histone modifications and to highlight the pathways and enzymes that are deregulated in cancer cells.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
THURSDAY, MARCH 31
FRIDAY, APRIL 1
Analysis of the Substrate Specificity of a Protein Lysine Methyltransferase
SATURDAY, APRIL 2
SUNDAY, APRIL 3
MONDAY, APRIL 4
TUESDAY, APRIL 5
Conference Program Print | View meeting in 12 hr (am/pm) time
THURSDAY, MARCH 31
19:30—20:30
Keynote Address
Richard A. Young,
Whitehead Institute for Biomedical Research, USA
Genome Regulatory Networks in Living Cells
Genome Regulatory Networks in Living Cells
08:00—11:00
Histone and Factor Acetylation
*
Mary Ann Osley,
University of New Mexico School of Medicine, USA
Michael Grunstein,
University of California, Los Angeles, USA
Acetylation on the Histone Globular Core Regulates Gene Activity
Acetylation on the Histone Globular Core Regulates Gene Activity
Lorraine Pillus,
University of California, San Diego, USA
Essential Functions for Chromatin Modifications
Essential Functions for Chromatin Modifications
Sharon Y.R. Dent,
University of Texas MD Anderson Cancer Center, USA
New Functions for Histone Modifying Activities
New Functions for Histone Modifying Activities
Melanie M. Ott,
Gladstone Institutes, USA
The “Yin and Yin” of HIV Tat Acetylation and Deacetylation
The “Yin and Yin” of HIV Tat Acetylation and Deacetylation
W. Lee Kraus,
University of Texas Southwestern Medical Center, USA
Short Talk: Reversible NAD+-Dependent Modulation of Chromatin Structure and Transcription by Poly(ADP-ribose) Polymerase-1 (PARP-1)
Short Talk: Reversible NAD+-Dependent Modulation of Chromatin Structure and Transcription by Poly(ADP-ribose) Polymerase-1 (PARP-1)
14:30—16:30
Workshop 1
Ji-Joon Song,
Korea Advanced Institute of Science and Technology, South Korea
Argonautica: Sclicer Revealed
Argonautica: Sclicer Revealed
Vincent Géli,
Centre National de la Recherche Scientifique, France
Structure and Functional Characterization of the RNA Recognition Motif of the Histone H3 Lysine Methyltransferase Set1
Structure and Functional Characterization of the RNA Recognition Motif of the Histone H3 Lysine Methyltransferase Set1
Nevan J. Krogan,
University of California, San Francisco, USA
Protein Complexes and Functional Pathways in Chromatin Metabolism
Protein Complexes and Functional Pathways in Chromatin Metabolism
Ann Dean,
NIDDK, National Institutes of Health, USA
Histone Modifications in Enhancer Activation and Enhancer Blocking
Histone Modifications in Enhancer Activation and Enhancer Blocking
Xuetong Shen,
University of Texas MD Anderson Cancer Center, USA
INO80 and gamma-H2AX Interaction Links ATP-dependent Chromatin Remodeling to DNA Damage Repair
INO80 and gamma-H2AX Interaction Links ATP-dependent Chromatin Remodeling to DNA Damage Repair
Claudius Vincenz,
University of Michigan, USA
Visualization of the Histon Code in Cells
Visualization of the Histon Code in Cells
Takashi Ito,
Nagasaki University School of Medicine, Japan
Nucleosomal Histone Kinase-1 Phosphorylates H2A Thr 119 During Mitosis in the Early Drosophila Embryo
Nucleosomal Histone Kinase-1 Phosphorylates H2A Thr 119 During Mitosis in the Early Drosophila Embryo
Analysis of the Substrate Specificity of a Protein Lysine Methyltransferase
Raymond C. Trievel,
University of Michigan, USA
Structural Basis of Substrate Recognition by SET Domain Methyltransferase
Structural Basis of Substrate Recognition by SET Domain Methyltransferase
17:00—19:00
Histone Ubiquitination
Shelley L. Berger,
University of Pennsylvania, USA
Histone Ubiquitylation/Deupbiquitylation and Sumoylation Genomic Regulation
Histone Ubiquitylation/Deupbiquitylation and Sumoylation Genomic Regulation
Mary Ann Osley,
University of New Mexico School of Medicine, USA
H2B Ubuquitylation is Associated with Transcription Elongation
H2B Ubuquitylation is Associated with Transcription Elongation
Ali Shilatifard,
Northwestern University, USA
Yeast COMPASS Points the Way to Human MLL and its Role in Pathogens of Leukemia
Yeast COMPASS Points the Way to Human MLL and its Role in Pathogens of Leukemia
Jaehoon Kim,
Korea Advanced Institute of Science and Technology, South Korea
Short Talk: Human Homologue of Yeast BRE1 has Coactivator Function in Activator-Dependent Transcription
Short Talk: Human Homologue of Yeast BRE1 has Coactivator Function in Activator-Dependent Transcription
08:00—11:00
Histone Methylation
C. David Allis,
Rockefeller University, USA
Beyond the Double Helix: Writing and Reading the ‘Histone Code’
Beyond the Double Helix: Writing and Reading the ‘Histone Code’
Tony Kouzarides,
University of Cambridge, UK
Histone Methylation and Back
Histone Methylation and Back
Yi Zhang,
HHMI/Harvard Medical School, Children's Hospital Boston, USA
Dissecting the Junction of Histone Methylation
Dissecting the Junction of Histone Methylation
Yang Shi,
Children's Hospital Boston, Harvard Medical School, USA
Histone demethylation mediated by the nuclear amine oxidase homolog LSD1
Histone demethylation mediated by the nuclear amine oxidase homolog LSD1
David Y. Lee,
University of New Mexico Cancer Center, USA
Short Talk: Identification and Characterization of a Coactivator Protein which Binds to Arginine-Methylated Histone H3
Short Talk: Identification and Characterization of a Coactivator Protein which Binds to Arginine-Methylated Histone H3
17:00—19:00
Recruitment of Enzyme Complexes
*
Robert E. Kingston,
Massachusetts General Hospital, USA
Ramin Shiekhattar,
University of Miami, USA
The histone demethylase complexes and their role in gene expression and cell fate
The histone demethylase complexes and their role in gene expression and cell fate
Geneviève Almouzni,
Centre National de la Recherche Scientifique, France
Chromatin in Assembly Factors and Maintanance of Genome Organization
Chromatin in Assembly Factors and Maintanance of Genome Organization
Danny F. Reinberg,
HHMI/New York University, USA
Regulation of mRNA Biogenesis by the Coordinator Complex, which Binds to Methylated Lysine-4 of Histone H3
Regulation of mRNA Biogenesis by the Coordinator Complex, which Binds to Methylated Lysine-4 of Histone H3
Yannick Doyon,
Laval University, Canada
Short Talk: A Central Role for the Inhibitor of Growth Tumor Suppressor Family in Chromatin Modifying Complexes
Short Talk: A Central Role for the Inhibitor of Growth Tumor Suppressor Family in Chromatin Modifying Complexes
08:00—11:00
ATP-Dependent Chromatin Remodeling
Toshio Tsukiyama,
Fred Hutchinson Cancer Research Center, USA
Mechanism of Chramatin Interaction by Isw2 Complex in vivo
Mechanism of Chramatin Interaction by Isw2 Complex in vivo
Bradley R. Cairns,
HHMI/University of Utah, USA
Chromatin Remodeling Involves Directional DNA Translocation from an Internal Nucleosomal Site
Chromatin Remodeling Involves Directional DNA Translocation from an Internal Nucleosomal Site
Robert E. Kingston,
Massachusetts General Hospital, USA
Different Ways to Remodel Chromatin in an "Altered Function" APT-Dependent Remodeler
Different Ways to Remodel Chromatin in an "Altered Function" APT-Dependent Remodeler
Blaine Bartholomew,
University of Texas MD Anderson Cancer Center, USA
Short Talk: ATP-Dependent Nucleosome Mobilization Initiates Deep Within the Nucleosome
Short Talk: ATP-Dependent Nucleosome Mobilization Initiates Deep Within the Nucleosome
14:30—16:30
Workshop 2
*
Fyodor D. Urnov,
University of California, Berkeley, USA
Keiko Ozato,
NICHD, National Institutes of Health, USA
Mammalian Double Bromodomain Protein Brd4 Recognizes Acetylated Histone Codes and Remains on Chromatin during Mitosis
Mammalian Double Bromodomain Protein Brd4 Recognizes Acetylated Histone Codes and Remains on Chromatin during Mitosis
Catharine L. Smith,
University of Arizona, USA
Regulation of Histone H3 Phosphorylation and Cell Cycle Depression through a Novel CAMP Signaling Pathway
Regulation of Histone H3 Phosphorylation and Cell Cycle Depression through a Novel CAMP Signaling Pathway
Nick Barlev,
NEMC-Tufts School of Medicine, USA
Regulation of p53 by Methyltransferase Set7/9
Regulation of p53 by Methyltransferase Set7/9
Hinrich Gronemeyer,
Institut de Génétique et de Biologie Molécullaire et Cellulaire, Strasbourg, France
Epigenetic Modulation of Tumor-Selective Death Signaling
Epigenetic Modulation of Tumor-Selective Death Signaling
Keji Zhao,
NHLBI, National Institutes of Health, USA
Acetylation Islands Revealed Genome-wide Mapping Are Functional Regulatory Elements
Acetylation Islands Revealed Genome-wide Mapping Are Functional Regulatory Elements
Masami Horikoshi,
University of Tokyo, Japan
Toward Elucidating the Mechanism of DNA Mediated Reactions
Toward Elucidating the Mechanism of DNA Mediated Reactions
Brent Brower-Toland,
Monsanto Company, USA
Participation of RNA Interference in the Formation of Heterochromatin in Drosophila
Participation of RNA Interference in the Formation of Heterochromatin in Drosophila
André Verdel,
Harvard Medical School, USA
Two RNAi Complexes Required for Heterochromatin Assembly, RITS and RDRC, Interact and are Recruited to Centromeric RNAs
Two RNAi Complexes Required for Heterochromatin Assembly, RITS and RDRC, Interact and are Recruited to Centromeric RNAs
17:00—19:00
Epigenetic Modifications and RNAi
Thomas Jenuwein,
Max Planck Institute of Immunobiology and Epigenetics, Germany
The Epigenome in the Context of the Post-Genomic Era
The Epigenome in the Context of the Post-Genomic Era
Shiv I. S. Grewal,
NCI, National Institutes of Health, USA
Role of RNAi Machinery in Heterochromatin Assembly
Role of RNAi Machinery in Heterochromatin Assembly
Robin C. Allshire,
University of Edinburgh, UK
RNA Interference, Heterochromatin and Centromere Architecture
RNA Interference, Heterochromatin and Centromere Architecture
Neil Brockdorff,
University of Oxford, UK
Short Talk: Function of Polycomb-Group Complex PRC1 in H2A Ubiquitylation and X Inactivation
Short Talk: Function of Polycomb-Group Complex PRC1 in H2A Ubiquitylation and X Inactivation
08:00—11:00
Chromatin in Transition: Histone Varients and Depletion
*
Carl Wu,
National Cancer Institute, NIH, USA
ATP-Dependent Chromatin Remodeling Complexes for Transcription
ATP-Dependent Chromatin Remodeling Complexes for Transcription
Steven Henikoff,
Fred Hutchinson Cancer Research Center, USA
Chromatin States Distinguished by Histone H3 Variants
Chromatin States Distinguished by Histone H3 Variants
Jerry L. Workman,
Stowers Institute for Medical Research, USA
Promotor and ORF Specific Rpd3 Complexes
Promotor and ORF Specific Rpd3 Complexes
Hiten D. Madhani,
University of California, San Francisco, USA
Control of Gene Silencing by Chromatin Modifications in Euchromatin
Control of Gene Silencing by Chromatin Modifications in Euchromatin
Philippe E. Bouvet,
Ecole Normale Superieure de Lyon, France
Short Talk: Structural and Functional Properties of macroH2A and H2ABbd Nucleosomes Variants
Short Talk: Structural and Functional Properties of macroH2A and H2ABbd Nucleosomes Variants
17:00—19:00
Histone Modifications and Cancer
*
Lorraine Pillus,
University of California, San Diego, USA
Victoria M. Richon,
Sanofi, USA
Development of SAHA for the Treatment of Cancer
Development of SAHA for the Treatment of Cancer
Andreas J. Ledl,
, Germany
Short Talk: Viral Oncoproteins E1A and E7 and Cellular LxCxE Proteins Repress SUMO Modification of the Retinoblastoma Tumor Suppressor
Short Talk: Viral Oncoproteins E1A and E7 and Cellular LxCxE Proteins Repress SUMO Modification of the Retinoblastoma Tumor Suppressor
Fyodor D. Urnov,
University of California, Berkeley, USA
Reading and Writing the Epigenome: Chromatin as a Drug Target
Reading and Writing the Epigenome: Chromatin as a Drug Target
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
We gratefully acknowledge additional support for this conference from:
|
|
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
